Tocilizumab in Chronic Inflammatory CPPD Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE2

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-04-30

Study Completion Date

2029-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this clinical trial is to determine the efficacy of tocilizumab (an IL-6 inhibitor) in treatment-refractory chronic inflammatory forms of CPPD.

The main questions this trial aims to answer are:

* Can tocilizumab improve joint pain in patients with chronic inflammatory CPPD disease?
* Does tocilizumab improve quality of life in patients with chronic inflammatory CPPD disease?

Participants will receive a monthly infusion of tocilizumab or placebo for three months.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pilot Study of Tocilizumab Monotherapy for Active Chronic Periaortitis

NCT05133895

Chronic Periaortitis Tocilizumab Monotherapy

COMPLETED

A Study of Tocilizumab (RoActemra/Actemra) in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous Tumor Necrosis Factor (TNF) Antagonist Therapy

NCT01209689

Spondylitis, Ankylosing

TERMINATED PHASE3

A Study of RoActemra/Actemra (Tocilizumab) in Patients With Ankylosing Spondylitis Who Have Failed Treatment With NSAIDs

NCT01209702

Spondylitis, Ankylosing

TERMINATED PHASE3

Tofacitinib for Reduction of Spinal Inflammation in Patients With Psoriatic ArthritiS PresenTing With Axial InvOlvement

NCT04062695

Psoriatic Arthritis Spondylitis Sacroilitis

UNKNOWN PHASE2

A Study of Infliximab (Remicade) in Patients With Ankylosing Spondylitis.

NCT00207701

Ankylosing Spondylitis

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Calcium pyrophosphate deposition (CPPD) disease affects 4 to 7% of the adult population. CPP crystals are responsible for inflammatory flares affecting one or more joints. The inflammation triggered by CPP crystals resembles that associated with sodium urate crystals in gout and depends on inflammatory cytokines such as interleukins (IL-) 1β and -6. The usual treatments are those used in gout flares (colchicine, NSAIDs, corticosteroids, IL-1β inhibitors), and most often control monoarticular involvement. The chronic inflammatory polyarticular form, on the other hand, is more difficult to treat, causing significant pain and disability, as well as joint destruction. In refractory forms, or in cases of intolerance to standard treatments, alternative therapies are required. In this context, the investigators treated 11 patients with refractory chronic inflammatory CPPD with tocilizumab (TCZ), an anti-IL-6 receptor (IL-6R) monoclonal antibody. After 3 monthly infusions, improvement was estimated at over 75% (PMID 2213498). Our hypothesis is that inhibiting IL-6 is an effective therapeutic option in chronic inflammatory CPPD refractory to conventional therapies.

Main objective and primary endpoint:

* To demonstrate the efficacy of IL-6 inhibition in treatment-refractory chronic inflammatory forms of CPPD disease.
* Our endpoint will be the change in global pain VAS between initiation and M4, i.e. one month after the 3rd infusion. VAS will be assessed after 24 hours off analgesics.

Secondary objectives and endpoints:

* Efficacy: DAS44, number of swollen, painful joints, overall disease activity VAS, fatigue VAS; overall effect on pain: area under the VAS curve (AUC); proportion of patients responding from M2 to M6 (improvement ≥ 50% of initial pain VAS) and complete response (improvement ≥ 80% of initial pain VAS); relapse rate; improvement in quality of life (SF-36, HAQ, EQ-5D-3L questionnaires)
* Tolerance: infusion reactions, infections, neutropenia, hepatic cytolysis, lipid profile

This is a phase III, multicentre, randomized, controlled, double-blind, superiority study, including 2 parallel groups with a 1:1 distribution. This trial will involve adults suffering from the chronic inflammatory polyarticular form of CPPD disease.

This study will involve 80 participants recruited in 12 centres in France.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Calcium Pyrophosphate Deposition Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

TociCCAre is a phase II, randomised, double-blind, placebo-controlled comparative study. The study aims to demonstrate the efficacy of tocilizumab in treating chronic polyarticular inflammation associated with CPP crystals.

It is a superiority study with 1:1 randomisation into two parallel groups.

This multicentre study has 12 participating centres, including centres specialising in microcrystalline diseases and a reference centre for Gitelman syndrome (one of whose complications is extensive PPC crystal deposition), located at the HEGP hospital in Paris.

Patients will be enrolled during consultations and hospitalisations by the principal investigator or their co-investigators.

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Pharmacy Process: Upon email notification, the pharmacy prepares and dispenses the tocilizumab or placebo. If unable to reconstitute it, they provide a nominative patient kit for external reconstitution.

Non-protocol Handlers: Specially trained nurses reconstitute treatment bags discreetly. Each center has a designated trainer to build a team of these off-protocol handlers.

Pharmacy Oversight: The hospital pharmacist ensures proper management of investigational products. Compliance is checked by a CRA during monitoring.

Blinding Strategy:

A blind CRA monitors clinical activities. An open CRA manages pharmacy stock and is aware of treatment allocation. The trial is double-blind to prevent bias for both patients and investigators.

Tocilizumab, 8 mg/kg/month, IV infusion for 3 months

Tocilizumab, an anti-IL-6R monoclonal antibody, was approved in January 2009 for the treatment of rheumatoid arthritis. Its indications have since been extended, particularly for the treatment of giant cell arteritis, juvenile chronic arthritis, and severe cytokine release syndrome induced by chimeric antigen receptor T-cell (CAR-T) therapy.

Intervention Type DRUG

Placebo

Saline placebo, IV infusion / month for 3 months

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults \> 18 years
* Diagnosis of CPPD according to ACR/EULAR 2023 classification criteria
* Persistent inflammatory pain (\> 3 months) or ≥ 2 arthritics/month
* Number of painful joints (NAD) \> 3
* Overall pain VAS (0\_100) \> 40 mm
* Failure, intolerance or impossibility of repeated use of usual treatments: colchicine, NSAIDs, corticosteroids and anakinra
* Use of an effective method of contraception in women of childbearing age until 3 months after the end of the study.
* Informed consent

Exclusion Criteria

* Presence of anti-CPP antibodies \> 50 IU/ml
* Recurrent or chronic infections
* History of severe infection (= requiring hospitalization)
* Active infection
* Vaccination with live or attenuated vaccine within 4 weeks prior to inclusion
* History of intestinal ulceration or diverticulitis Untreated latent tuberculosis
* History of viral hepatitis B ou C
* Symptoms suggestive of demyelinating disease of the central nervous system
* History of cancer, active cancer, or suspected cancer
* Neutropenia \< 2000 elements/mm3, thrombocytopenia \< 100 000/mm3
* Elevated transaminases \> 3 x ULN
* Known hypersensitivity to the active substance or one of the excipients;
* Known severe immune deficiency
* Patients not meeting classification criteria
* Concomitant treatment with biological or targeted therapies, or immunosuppressive therapy (including methotrexate, leflunomide, azathioprine), systemic corticosteroids, anakinra, IL-6 inhibitors in subcutaneous injection, anti-TNF agents, and JAK. If these treatments are used before inclusion, a washout period corresponding to at least five times their respective mean terminal half-life must be respected.
* inhibitors.
* Previous treatment with tocilizumab
* Concomitant treatment with methylprednisolone, dexamethasone, atorvastatin, calcium channel blockers, theophylline, warfarin, phenprocoumon, phenytoin, cyclosporine or benzodiazepines
* Dyslipidemia, hypertension or poorly controlled cardiovascular disease
* Scheduled surgery
* Difficulty to understand French, illiteracy
* Pregnant women, women in labor or nursing mothers
* Persons deprived of their liberty, adults under legal protection or unable to express their consent
* Persons not affiliated to a social security scheme or beneficiaries of such a scheme
* Participation in another interventional study

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No